Artesunate+amodiaquine (AS+AQ)	artemether-lumefantrine (AL) and and Artesunate+chlorproguanil-dapsone (AS+CD)	the parasitological and clinical failure rate at day 28 post treatment	1081	1365	the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005).
Artesunate+amodiaquine (AS+AQ)	artemether-lumefantrine (AL)	parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children	22632	22783	There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups
Artesunate+amodiaquine (AS+AQ)	artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD)	the parasitological and clinical failure rate at day 28 post treatment	1543	1729	However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4)
